← Adaptive Biotechnologies Corp
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.4m |
$55.7m
+44.77%
|
$85.1m
+52.83%
|
$98.4m
+15.65%
|
$154.3m
+56.88%
|
$185.3m
+20.06%
|
$170.3m
-8.11%
|
$179.0m
+5.10%
|
$277.0m
+54.77%
|
$308.1m
+11.23%
|
|
| Cost of revenue | $15.7m |
$19.7m
+25.43%
|
$22.3m
+13.25%
|
$22.5m
+1.15%
|
$49.3m
+118.82%
|
$57.9m
+17.46%
|
$75.6m
+30.47%
|
$72.1m
-4.60%
|
$71.4m
-1.00%
|
$75.3m
+5.46%
|
|
| Gross Profit | $22.8m |
$36.0m
+58.09%
|
$62.8m
+74.46%
|
$75.9m
+20.79%
|
$105.0m
+38.48%
|
$127.4m
+21.28%
|
$94.7m
-25.65%
|
$106.9m
+12.83%
|
$205.6m
+92.39%
|
$232.8m
+13.23%
|
|
| Research and development | $32.0m | $39.2m | $70.7m | $116.1m | $142.3m | $141.8m | $122.1m | $103.0m | $93.8m | $88.2m | |
| Sales and marketing | $16.8m | $24.5m | $38.5m | $61.4m | $95.5m | $95.6m | $88.6m | $84.8m | $94.6m | — | |
| General and administrative | $15.9m | $20.4m | $30.3m | $49.5m | $74.5m | $88.5m | $83.9m | $72.8m | $72.7m | $79.7m | |
| Amortization of intangible assets | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | — | |
| Total operating expenses | $82.9m | $105.4m | $163.5m | $251.2m | $363.3m | $385.5m | $397.3m | $341.5m | $334.1m | $345.5m | |
| Loss from operations | ($44.5m) |
($49.8m)
-11.87%
|
($78.4m)
-57.55%
|
($152.8m)
-94.94%
|
($209.0m)
-36.74%
|
($200.2m)
+4.20%
|
($227.0m)
-13.41%
|
($162.5m)
+28.40%
|
($57.1m)
+64.86%
|
— | |
| Interest expense | — | — | — | — | — | ($4.2m) | ($13.8m) | ($11.6m) | ($11.8m) | $11.5m | |
| Interest and other income, net | $1.6m | $3.3m | $9.8m | $6.6m | $1.7m | $4.1m | $15.5m | $14.5m | $9.4m | — | |
| Net loss | ($42.8m) | ($46.4m) | ($68.6m) | ($146.2m) | ($207.3m) | ($200.4m) | ($225.3m) | ($159.6m) | ($59.5m) | — | |
| Net loss attributable to Adaptive Biotechnologies Corporation | ($42.8m) | ($46.4m) | ($68.6m) | ($146.2m) | ($207.3m) | ($200.2m) | ($225.2m) | ($159.5m) | ($59.5m) | — | |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | — | — | $1 | ($1) | ($1) | ($1) | ($2) | ($1) | ($0) | — | |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | — | — | $1 | ($1) | ($1) | ($1) | ($2) | ($1) | ($0) | — | |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | — | — | — | ($1) | ($1) | ($1) | ($2) | ($1) | ($0) | — | |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | — | — | — | ($1) | ($1) | ($1) | ($2) | ($1) | ($0) | — | |
| Impairment of long-lived assets | — | — | — | — | — | — | $25.4m | $7.2m | $0 | — | |
| Add: Net (income) loss attributable to noncontrolling interest | — | ($46.4m) | ($68.6m) | ($146.2m) | $19k | $177k | $54k | $103k | ($42k) | — |